 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...13141516171819202122232425» |
- BB-MPI-03 / Benovus Bio
New P1 trial: BBMPI03: Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (clinicaltrials.gov) - Sep 15, 2014
P1, N=30, Not yet recruiting, Sponsor: Benovus Bio, Inc.
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial primary completion date, Metastases: Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) - Sep 9, 2014
P2, N=53, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Jan 2016
- || Leukine (sargramostim) / Partner Therap, lorukafusp alfa (APN301) / Apeiron Biologics
Trial primary completion date: Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=52, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2014 --> Jan 2016 Trial primary completion date: Dec 2014 --> Dec 2013
- Recentin (cediranib) / AstraZeneca
Enrollment change, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2013 N=47 --> 70
- Leukine (sargramostim) / Partner Therap
Enrollment closed, Trial primary completion date: Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer (clinicaltrials.gov) - Aug 21, 2014
P1/2, N=60, Active, not recruiting, Sponsor: COL George Peoples, MD, FACS
N=47 --> 70 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Dec 2014
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Aug 15, 2014
P2, N=29, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2014 --> Dec 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial termination, Combination therapy: Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Aug 12, 2014
P2, N=0, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Completed --> Terminated
- || Leukine (sargramostim) / Partner Therap, lorukafusp alfa (APN301) / Apeiron Biologics
Trial primary completion date: Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Aug 1, 2014
P2, N=52, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Terminated Trial primary completion date: Dec 2013 --> Dec 2014
- ||||| Enrollment change: Combination Chemotherapy in Treating Children With Neuroblastoma (clinicaltrials.gov) - Aug 1, 2014
P3, N=573, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2013 --> Dec 2014 N=400 --> 573
- | Trial completion: Combination Chemotherapy in Treating Children With Neuroblastoma (clinicaltrials.gov) - Jul 31, 2014
P3, N=573, Completed, Sponsor: Children's Oncology Group
N=400 --> 573 No longer recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial primary completion date: Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=16, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
No longer recruiting --> Completed Trial primary completion date: Dec 2014 --> Jul 2013
- IMA950 / Immatics, University Hospitals of Geneva
Trial primary completion date: CRUK-CR0902-11: Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Jul 23, 2014
P1, N=45, Active, not recruiting, Sponsor: Cancer Research UK
Trial primary completion date: Dec 2014 --> Jul 2013 Trial primary completion date: Dec 2013 --> Feb 2015
- | melphalan / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors (clinicaltrials.gov) - Jul 22, 2014
P2, N=31, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2013 --> Feb 2015 No longer recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer (clinicaltrials.gov) - Jul 15, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Jul 12, 2014
P2, N=340, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2015
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma (clinicaltrials.gov) - Jul 2, 2014
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: May 2015 --> May 2016
- Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Jul 1, 2014
P2, N=74, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> May 2016 Suspended --> Recruiting
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
New P1/2 trial: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Jun 27, 2014
P1/2, N=40, Not yet recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- Leukine (sargramostim) / Partner Therap
Trial completion, Surgery: GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer (clinicaltrials.gov) - Jun 27, 2014
P1, N=24, Completed, Sponsor: University of California, San Francisco
Suspended --> Recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (clinicaltrials.gov) - Jun 23, 2014
P2, N=10, Not yet recruiting, Sponsor: Fundaci
- Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial initiation date: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) - Jun 23, 2014
P2, N=54, Not yet recruiting, Sponsor: Lawrence Fong
Active, not recruiting --> Completed Initiation date: Dec 2012 --> Feb 2014
- Leukine (sargramostim) / Partner Therap, Ampligen (rintatolimod) / AIM ImmunoTech
Trial primary completion date, Combination therapy: Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=50, Active, not recruiting, Sponsor: University of Washington
Initiation date: Dec 2012 --> Feb 2014 Trial primary completion date: Oct 2014 --> Nov 2013
- Leukine (sargramostim) / Partner Therap, Ampligen (rintatolimod) / AIM ImmunoTech
Enrollment change, Combination therapy: Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=50, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Oct 2014 --> Nov 2013 N=98 --> 50
- Leukine (sargramostim) / Partner Therap, Ampligen (rintatolimod) / AIM ImmunoTech
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (clinicaltrials.gov) - Jun 19, 2014
P1/2, N=50, Active, not recruiting, Sponsor: University of Washington
N=98 --> 50 Recruiting --> Active, not recruiting | N=98 --> 50 | Trial primary completion date: Oct 2014 --> Nov 2013
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Jun 18, 2014
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting | N=98 --> 50 | Trial primary completion date: Oct 2014 --> Nov 2013 Trial primary completion date: Dec 2013 --> Dec 2015
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 18, 2014
P1, N=9, Completed, Sponsor: University of Virginia
Trial primary completion date: Dec 2013 --> Dec 2015 Active, not recruiting --> Completed
- Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Jun 4, 2014
P2, N=47, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Apr 2016
- Leukine (sargramostim) / Partner Therap
Trial completion: FAMPAP: Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) (clinicaltrials.gov) - Jun 2, 2014
P2, N=2, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Trial primary completion date: Jun 2014 --> Apr 2016 Enrolling by invitation --> Completed
- |||| NeuVax (nelipepimut-S) / Dr. Reddy's
Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - May 27, 2014
P3, N=700, Recruiting, Sponsor: Galena Biopharma, Inc.
Enrolling by invitation --> Completed Trial primary completion date: May 2015 --> Jun 2017
- ||| NeuVax (nelipepimut-S) / Dr. Reddy's
Trial completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - May 27, 2014
P3, N=700, Recruiting, Sponsor: Galena Biopharma, Inc.
Trial primary completion date: May 2015 --> Jun 2017 Trial completion date: May 2022 --> Jun 2024
- | temozolomide / Generic mfg.
New P1 trial, Immunomodulating: GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) - May 27, 2014
P1, N=20, Not yet recruiting, Sponsor: immatics Biotechnologies GmbH
- Recentin (cediranib) / AstraZeneca
Trial completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - May 21, 2014
P2, N=47, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2022 --> Jun 2024 Trial completion date: Jun 2014 --> Apr 2016
- | Leukine (sargramostim) / Partner Therap
Trial completion, Surgery: Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma (clinicaltrials.gov) - May 20, 2014
P2, N=60, Completed, Sponsor: University of Southern California
Trial completion date: Jun 2014 --> Apr 2016 No longer recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? (clinicaltrials.gov) - May 19, 2014
P1/2, N=70, Recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
No longer recruiting --> Completed Trial primary completion date: Sep 2013 --> Apr 2015
- Leukine (sargramostim) / Partner Therap
Trial completion date: Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? (clinicaltrials.gov) - May 19, 2014
P1/2, N=70, Recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Trial primary completion date: Sep 2013 --> Apr 2015 Trial completion date: Oct 2013 --> Apr 2015
- Leukine (sargramostim) / Partner Therap
Enrollment change: Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? (clinicaltrials.gov) - May 19, 2014
P1/2, N=70, Recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Trial completion date: Oct 2013 --> Apr 2015 N=92 --> 70
- Leukine (sargramostim) / Partner Therap
Enrollment open: Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? (clinicaltrials.gov) - May 19, 2014
P1/2, N=70, Recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
N=92 --> 70 Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 18, 2014
P2, N=52, Active, not recruiting, Sponsor: University of Southern California
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2014 --> Jan 2015
- Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - May 18, 2014
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2014 --> Jan 2015 Trial primary completion date: Nov 2013 --> Jan 2011
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial completion date: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 18, 2014
P2, N=52, Active, not recruiting, Sponsor: University of Southern California
Trial primary completion date: Nov 2013 --> Jan 2011 Trial completion date: Jan 2015 --> Jan 2016
- Leukine (sargramostim) / Partner Therap
Enrollment change: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - May 14, 2014
P1, N=12, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Jan 2015 --> Jan 2016 N=36 --> 12
- Leukine (sargramostim) / Partner Therap, IMA950 / Immatics, University Hospitals of Geneva
Trial termination, IO biomarker: Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma (clinicaltrials.gov) - May 13, 2014
P1, N=6, Terminated, Sponsor: immatics Biotechnologies GmbH
This decision was taken without any safety reasons. Since beginning of the study (June 2011) only six patients were enrolled.
- Leukine (sargramostim) / Partner Therap, IMA950 / Immatics, University Hospitals of Geneva
Enrollment change, IO biomarker: Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma (clinicaltrials.gov) - May 13, 2014
P1, N=6, Terminated, Sponsor: immatics Biotechnologies GmbH
Since beginning of the study (June 2011) only six patients were enrolled. N=25 --> 6
- Rituxan (rituximab) / Roche
Trial primary completion date: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=25 --> 6 Trial primary completion date: Jul 2014 --> May 2014
- Rituxan (rituximab) / Roche
Trial completion date: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Jul 2014 --> May 2014 Trial completion date: Jul 2014 --> May 2014
- Rituxan (rituximab) / Roche
Enrollment change: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial completion date: Jul 2014 --> May 2014 N=63 --> 50
- Rituxan (rituximab) / Roche
Trial completion: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=63 --> 50 Active, not recruiting --> Completed
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial primary completion date, Metastases: Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Sep 2014
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion date, Metastases: Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2014 --> Sep 2014 Trial completion date: Apr 2014 --> Sep 2014
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
New P1 trial: A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas (clinicaltrials.gov) - May 4, 2014
P1, N=36, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital